Invest in ME Conference 12: First Class in Every Way
OverTheHills wraps up our series of articles on this year's 12th Invest in ME International Conference (IIMEC12) in London with some reflections on her experience as a patient attending the conference for the first time.
Discuss the article on the Forums.

Belimumab for Systemic Lupus

Discussion in 'Other Health News and Research' started by merylg, Dec 4, 2011.

  1. merylg

    merylg Senior Member

    Sydney, NSW, Australia

    "Clin Pharmacol Ther. 2011 Nov 30. doi: 10.1038/clpt.2011.290. [Epub ahead of print]
    Belimumab: A BLyS-Specific Inhibitor for the Treatment of Systemic Lupus Erythematosus.
    Dennis GJ.

    Department of Medical Affairs, Human Genome Sciences, Rockville, Maryland, USA.

    Belimumab (Benlysta), which recently received marketing approval, is the first of a new class of immunomodulators with a novel mechanism of action. It is a specific inhibitor of the soluble B-lymphocyte stimulator (BLyS) cytokine, which has been implicated in the pathogenesis of systemic lupus erythematosus (SLE). Two large phase III randomized controlled clinical trials evaluated the safety and efficacy of belimumab combined with standard therapy and showed that the efficacy of this treatment was significantly superior to placebo plus standard therapy. Belimumab is an evidence-based therapeutic option for patients with general lupus disease activity and may signal a shift in the existing treatment paradigm from therapeutic selection targeting specific organ involvement to an approach directed at tackling multisystem disease activity and preventing the disease from worsening.

    [PubMed - as supplied by publisher] "
  2. Snow Leopard

    Snow Leopard Hibernating

    South Australia
    I haven't read the paper, but this sounds interesting and should have lower side effects than other less specific treatments. It would be nice to see this drug approved by insurance companies for Lupus!

See more popular forum discussions.

Share This Page